Background: Cytopenias are the most common HIV-associated hematological abnormality. Cytopenias have been associated with several factors including sex, race/ethnicity, geographical location and comorbidities such as tuberculosis, hepatitis B infection, fever and oral candidiasis. Cytopenias become more prevalent as HIV progresses and are often fatal. Data from resource-limited settings about the prevalence and correlates of cytopenia are limited. Therefore we conducted this cross-sectional study to assess the prevalence and correlates of cytopenia among adult AIDS patients at initiation of HAART in Uganda. Methods: 400 HIV-infected subjects who were HAART-naïve or on HAART for ≤ 6 months were enrolled into the Multivitamins, HAART and HIV/AIDS Trial. Anemia was defined according to WHO guidelines as any hemoglobin concentration < 12 g/dl for non-pregnant females and < 13 g/dl for males. Leucopenia and thrombocytopenia were defined using study site laboratory reference ranges for lack of generally accepted definitions for these 2 cell lines as leucopenia if white blood cell count < 2.75 × 10 9 cells/litre and thrombocytopenia if platelets < 125 × 10
Background
Human Immunodeficiency Virus (HIV) infection is associated with hematological abnormalities, the most common manifestation being characterized by reduction in and impaired function of all blood cell lines: red blood cells (anemia), white blood cells (leucopenia or neutropenia) and platelets (thrombocytopenia) collectively called cytopenias. Neutropenia is defined by abnormally low numbers of neutrophils which normally make up 50-70% of circulating white blood cells. Cytopenias increase in frequency as HIV progresses and are often fatal without intervention [1] [2] [3] [4] .
Anemia is the most common cytopenia and its prevalence varies with different definitions used and in different settings. A systematic review of studies documenting the prevalence or incidence of anemia in HIV-infected patient populations reported prevalence rates from 1.3% to 95% [5] . In Europe and the United States, anemia occurs in about 35-65% of individuals before or at the start of highly active antiretroviral therapy (HAART) [2, 6] and in Africa and Asia the prevalence ranges from 18% to 77% [7] [8] [9] . In Uganda the DART trial reported a prevalence of 0.7% grade 4 anemia at week 4 in patients initiating triple combination antiretroviral therapy (ART) [10] , Mugisha et al. found 18 .9% anemic HIV-positive subjects in a rural cohort of HIV-infected and HIV negative adults [11] and Mukaya et al. reported 64.6% anemic patients attending the medical emergency ward of Uganda's national referral hospital, Mulago [12] . The presence of anemia has been associated with faster disease progression and has been shown to independently predict survival [1, 2, [13] [14] [15] [16] . The widespread use of highly active antiretroviral therapy (HAART) has led to significant improvements in patient survival and more specifically in improvement of anemia particularly severe anemia irrespective of the use of azidothymidine (AZT) in the regimen [2, 8, 10, [17] [18] [19] [20] . However, mild to moderate anemia occurs or persists in some individuals on long-term therapy and gradually impairs the individual's functional status [2, 8, 21] . This is clinically significant because anemia affects quality of life which in the context of HAART has become an increasingly important treatment goal [22, 23] .
Data about the prevalence of leucopenia and thrombocytopenia and factors associated with their presence in HIV-infected adults is limited. Leucopenia occurs in 57 to76% of patients with advanced HIV infection [24] [25] [26] , neutropenia specifically was found in 44% of HIV-infected women prior to initiating HAART [27] while prevalent thrombocytopenia ranges from 7% to about 21% increasing with the stage of HIV infection [7] [28] . Neutropenia may be caused by adverse drug reactions or myelosuppressive drugs [7] and it has been associated with low baseline CD4 count [29] . Thrombocytopenia has been independently associated with chronic active hepatitis B virus infection, male gender, low absolute neutrophil count and low CD4 count [15, 30] . However, a study in India did not find a significant correlation between thrombocytopenia and low CD4 count [7] .
Cytopenia in HIV-1 infected adults has been associated with geographical location (anemia and neutropenia were highest in Southern African countries and Haiti compared to the US) [30] , race/ethnicity (anemia was more prevalent in African-Americans [1, 31] and neutropenia was higher in non-Hispanics than Hispanics [30] ), female sex (anemia and neutropenia were higher in females) [1, 6, 9, 11, 30, 31] , age (anemia is more prevalent in older patients compared to younger patients) [6] and laboratory markers such as low mean corpuscular volume (MCV: < 80 femtolitres) [20, 31] , CD4 cell count (low CD4 count has been associated with prevalent anemia, neutropenia and thrombocytopenia) [7, 11, 29, 31] , high viral load [31] , use of AZT [31] , low body mass index (BMI) [9, 10] and co-morbid conditions such as tuberculosis [9, 20] , hepatitis B (thrombocytopenia was associated with hepatitis B surface antigen) [30] , malaria, fever, pneumonia and oral candidiasis [11] .
Data about the prevalence and factors associated with cytopenia in patients initiating HAART has largely been derived from developed countries that may differ from developing countries in patient profile, cytopenia etiology, antiretroviral regimen options and comorbidities [1, 2, 13, 14, 19, 31, 32] .
The magnitude of pre-existing cytopenias and associated factors at the time of initiating HAART could impact on ART treatment outcomes. However, the magnitude of this problem has not been adequately described in resourcelimited settings. This cross-sectional study is designed to fill these gaps by investigating the prevalence and correlates of cytopenia among adult Ugandan AIDS patients either HAART-naïve at enrollment or on HAART for ≤ 6 months. We hypothesize that this population will have higher prevalences of each cytopenia and worse clinical parameters compared to similar cohorts in developed countries. This analysis was approved by the Infectious Diseases Institute Scientific Review Committee, and the Higher Degrees, Research and Ethics Committee (HDREC) of the Makerere School of Public Health.
Methods

Study design, setting and population
In this article we present hematological data which were collected at enrolment into a double blind placebo-controlled micronutrient trial among HIV-positive adults ≥ 18 years in Uganda. The adult HIV prevalence in Uganda is estimated at 7.3% [33] . Between March 2010 and June 2012, 400 HIVpositive adults were enrolled into the Multivitamins, HAART and HIV/AIDS Trial. The inclusion criteria for enrolment into the parent trial included being at least 18 years old at the time of enrolment, HIV-positive and eligible to initiate HAART or have been on HAART for not more than 6 months at the time of enrolment, living within a 20 kilometre radius of the health unit of enrolment, without an intention of migrating out of Kampala for at least 18 months after enrolment and provide informed written consent for participation. To be eligible for initiation of HAART, subjects had to present with either WHO stage 4 or CD4 count less than 200 cells/μl, or WHO stage 3 or CD4 count less than 350 cells/μl. Women who were pregnant and those who were ineligible to initiate HAART at the time of enrolment due to early-stage disease were excluded from the trial. Further details of the design and methods of the trial are described elsewhere [34] . Patients were clinically managed at the Infectious Diseases Institute (IDI), Makerere University College of Health Sciences and this trial was implemented at IDI in collaboration with the Makerere School of Public Health and the Harvard School of Public Health. All data presented here were collected at baseline, before the start of the micronutrient intervention.
At enrollment all subjects had a Complete Blood Count (CBC, Beckman Coulter Act 5 Diff, Miami, Florida, USA), and CD4 cell count (BD FACSCalibur System, Becton Dickinson, San Jose, California, USA) done provided this had not been done within a month prior to enrolment. Blood was collected in an EDTA vacutainer for both tests.
Measurements Anemia
Anemia was defined according to WHO guidelines as <12 g/dl for non-pregnant women and <13 g/dl for men. Anemia severity was graded as mild: 11-11.9 g/dl for women and 11-12.9 g/dl for men; moderate: 8-10.9 g/dl for both sexes; and < 8 g/dl as severe anemia for both sexes [35] .
Other cytopenias
There are no generally accepted cut-offs for other cytopenias. A study in India used a cut off of total white blood cells < 4000 cells/μl to define leucopenia and platelet count <150 × 10 3 cells/μl to define thrombocytopenia in HIV-infected individuals [7] . We used the study site laboratory reference ranges (Makerere University-John Hopkins University, MUJHU Core laboratory) to define leucopenia and thrombocytopenia. The MUJHU Core-laboratory is a CAP-certified laboratory (CAP certificate number 7139001). Other cytopenias were thus defined as: leucopenia if total white blood cell count < 2.75 × 10 9 cells/litre, thrombocytopenia if platelet count <125 × 10 9 cells/litre for females and <156 × 10 9 cells/litre for males; bicytopenia if a subject had a combination of any 2 cytopenias and pancytopenia as having all three forms of cytopenia simultaneously.
Statistical analysis
Univariate analysis was used to describe the subjects' characteristics. Continuous variables were summarized using means or medians as found appropriate and categorical variables were summarized using frequencies and percentages. Thus prevalences of the various forms of cytopenia are reported as percentages of subjects with cytopenias with the denominator being all subjects in the trial.
We used the log-binomial regression model to investigate the factors associated with cytopenias in general and then anemia, leucopenia and thrombocytopenia were considered as individual outcome variables. Prevalence ratios (PR) and their 95% confidence intervals (95%CI) are reported. The independent factors investigated included demographic variables (e.g. sex, age, marital and employment status, highest level of education attained) and clinical/laboratory characteristics (e.g. CD4 cell count, body mass index, presence or history of oral candidiasis, presence or history of fever, etc.). All data analysis was done using Stata version 11.2.
Results
Patient characteristics
This analysis included the 400 subjects enrolled in the parent trial of which 277(69.3%) were female and overall the mean age of the study population was 36 years ( Table 1) . The median CD4 cell count was 142 cells/μl and 50% of the subjects had initiated antiretroviral therapy at the time of enrolment. The mean duration on HAART was 2.5 months (±1.6 SD). The mean BMI was 23.8 (SD ±9.2),
Prevalence of cytopenias
A total of 260 (65%) had at least one form of cytopenia. Anemia was the most common cytopenia occurring in 192 (47.8%) of the subjects followed by leucopenia occurring in 96 (24.3%), thrombocytopenia in 32 (8.3%), bicytopenia in 88 (21.9%) and only 2 had a pancytopenia ( Table 2) . Cytopenias were more prevalent in subjects aged between 30 to 35 years and in those with CD4 count less than 50 cells/μl.
Factors associated with cytopenias
In this analysis the factors found to be associated with any cytopenia were female sex, CD4 cell count and body mass index (Table 3 ). The prevalence ratio of any cytopenia among females compared to males was 1. 
Discussion
Hematological abnormalities in HIV infected individuals such as cytopenia and in particular anemia have been shown to predict disease progression and mortality [2, 13, 15, [36] [37] [38] [39] . The causative role of HIV in vivo in altering the bone marrow microenvironment thus inhibiting hematopoiesis and directly resulting in cytopenia is uncertain [40] [41] [42] [43] [44] . However, cytopenias occur more frequently with advanced HIV or as viral replication persists and patients may present with multiple cytopenias [3, 4, 45] . We evaluated the types, frequencies and correlates of cytopenia in HIV-infected adults at initiation of HAART in an urban cohort in Uganda. A higher prevalence of all 3 forms of cytopenia was found in this population compared to two other studies in HIV-infected individuals prior to initiation of HAART; one in Korea and another, a multicenter study. The prevalence of anemia was 3% in the Korean study and 11.9% in the multicenter study; neutropenia occurred in 10% and 14.3% and thrombocytopenia in 2.4% and 7.2% respectively [30, 32] . These differences could be due to different cut-off values used to define the cytopenias particularly anemia. Furthermore patients with severe forms of anemia for instance were excluded from both studies and this could have under-estimated the true prevalence. Female sex, increasing immune suppression (measured by CD4 cell count) and decreasing body mass index (BMI) were independent predictors of having a cytopenia in this study. This is consistent with other studies that have found females to be more likely to have anemia (as a result of additional demands during pregnancy and menstrual loss) [9, 11, 30] and to have a higher odds of neutropenia than males [30] . This study also confirms the findings of other studies that have shown an association between low CD4 counts and the presence or development of anemia [6, 31] , neutropenia [29, 39] and thrombocytopenia [39] . Furthermore, the highest rates of cytopenia occurred in patients with advanced HIV (CD4 count <200 cell/μl) which is consistent with other studies in developing countries [7, 9, 15, 29] . Out of 191 subjects with anemia in our study, 77% (n = 148) had CD4 count <200. Similarly out of 97 subjects with leucopenia, 82% (n = 80) had CD4 < 200 and of the 33 subjects with thrombocytopenia, 75% (n = 25) had CD4 count <200. However, these differences by CD4 category <200 or ≥ 200 were not statistically significant. The association of low CD4 cell count with anemia and leucopenia may be due to the dysregulatory effect of HIV on the function of early hematopoietic progenitor cells through the viral accessory protein Negative factor (Nef) [3] . Anemia was the most prevalent cytopenia and female sex and decreasing BMI were the sole predictors of having anemia in this study. The prevalence of anemia was considerably higher compared to a rural Ugandan cohort which found 18.9% anemic HIV-positive individuals even though lower hemoglobin cut-offs were used in the rural cohort and the CD4 cell counts were comparable in both cohorts [11] . This could be due to differences in modifiable factors like types of diet, alcohol consumption, cigarette smoking and so on which may vary between urban and rural populations however, we could not confirm this. Subbaraman et al. attributed the association between low BMI and anemia to nutrient deficiencies and chronic malnutrition which is prevalent in resource-limited settings [9] . A study in Brazil found a lower prevalence of anemia (37.7%) compared to our study and this was partly attributed to improvements in the country's social and nutritional conditions over recent decades [15] . The etiology of anemia in HIV-infection is multifactorial and has been attributed to infiltrative conditions of the bone marrow (e.g. neoplasms, drugs or infections including HIV itself) [16, 46] , hemolytic causes (e.g. red blood cell autoantibodies [47] , drugs [48] ), decreased production of or response to endogenous erythropoietin [49] and nutritional deficiencies [50] . Without intervention, anemia can lead to significant symptoms like fatigue, breathlessness, difficulty in concentration and other effects on functionality and quality of life therefore treatment of anemia in HIV should be aimed at correcting the underlying cause [16] . Regarding leucopenia, neutropenia is the most clinically relevant subtype because it is a good indicator of the risk of infection. In this study, decreasing CD4 count was the sole predictor of having leucopenia. The presence of neutropenia in HIV infection exacerbates the susceptibility to infections such as bacteremia, meningitis but particularly to invasive fungal infections [51] . The etiology of neutropenia is multifactorial and correction of potentially reversible causes is critical to management of HIV-associated neutropenia [51] . Thrombocytopenia was less commonly observed than anemia and leucopenia in our study and this is comparable to findings in other studies [30, 32] . Being female PR 0.32 [95% CI: 0.15-0.68, p = 0.003] and being on HAART at the time of enrolment PR 0.32 [95% CI: 0.14-0.75, p = 0.008] were associated with decreased odds of having thrombocytopenia. Thrombocytopenia is caused mainly by inadequate platelet production or immunemediated platelet destruction [16] . Of the 400 subjects, 200 (50%) were already on HAART at the time of enrolment and 93% of these were on an AZT-based regimen. AZT has been shown to be the treatment of choice for HIV-related thrombocytopenia [52] and this could explain the relatively low prevalence of this cytopenia found in our study. However, because abnormal bleeding in these patients is not very common (i.e. when platelet counts are > 30,000 × 10 9 /L) [53] , treatment of mild to moderate HIV-related thrombocytopenia may not be necessary [16, 53, 54] .
The main limitation of this analysis is its cross-sectional design which makes determination of temporal relationships between cytopenias and associated factors difficult. Furthermore we did not assess the various causes of cytopenia and specifically anemia in this population.
Conclusion
In conclusion, this study provides an opportunity to compare the prevalence estimates and correlates of all forms of cytopenia in HIV-infected adults at initiation of HAART in Uganda. The prevalence of anemia was the highest and meets WHO criteria for a severe public health problem. Female sex, decreasing CD4 count and decreasing BMI were the main factors associated with having cytopenia. Prospective studies in resource-limited settings on the trend in hematological parameters are needed. Hematological parameters are potential markers for disease progression and treatment outcomes in HAART-treated individuals in these settings.
